翻转目标:评估用于选择性LDHB调节的天然LDHA抑制剂
Amanda El Khoury1, Christos Papaneophytou1
1Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus.
Molecules (Basel, Switzerland)
|July 30, 2025
概括
这项研究探讨了乳酸脱酶B (LDHB) 抑制的天然化合物. 与LDHA抑制剂不同的是,丁醇和奎尔丁通过结合到一个全位的选择性,非竞争性的LDHB抑制.
科学领域:
- 生物化学 生化学
- 酶学 是一种酶学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳酸脱酶 (LDH) 在细胞代谢中至关重要的酸盐和乳酸盐之间进行相互转化.
- 虽然LDHA是已知的癌症标,但LDHB在癌症代谢重编程中的作用尚未得到充分研究.
- 现有的LDH抑制剂向LDHA的活性部位,缺乏LDHB的特异性.
研究的目的:
- 系统地选天然化合物进行乳酸脱酶B (LDHB) 抑制.
- 研究天然化合物对LDHB的异型特异性抑制机制.
- 从天然产品库中识别新的,选择性的LDHB抑制剂.
主要方法:
- 集成的 in silico (虚拟选,分子对接) 和 in vitro (酶动力学) 方法.
- 对115种先前被确定为LDHA抑制剂的天然化合物的选.
- 使用经过验证的色度测定方法进行高通量选.
主要成果:
- 确定了16种具有潜在LDHB抑制功能的化物.
- 卢特和奎尔丁证明了LDHB的非竞争性抑制.
- 分子对接揭示了luteolin和quercetin与LDHB二聚体接口的全位结合.
结论:
- 素和氨酸表现出LDHB的异型特异性抑制,与LDHA抑制剂不同.
- 天然化合物对LDHB的全性抑制提供了一个新的治疗策略.
- 这项研究为设计自然来源的选择性LDHB抑制剂提供了基础.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
358
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379